{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-039716","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2022-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.034887+00:00","generated_at":"2026-06-26T13:28:18.147063+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"VYNE reports positive preclinical RA data for pan-BET inhibitor VYN201; on track for H2 2022 Ph1","bullets":["VYN201 intra-articular injection showed statistically significant inhibition of paw thickening at 1 and 10 mg/kg (p<0.01).","At 1 mg/kg, paw thickness reduced 26.8% vs untreated; at 10 mg/kg, reduced 37.6%.","Arthritis scores at 1 and 10 mg/kg were near normal (0.57 and 0.67), reductions of 76.5% and 79.9%.","VYN201 numerically superior to intra-articular dexamethasone in both endpoints.","Company confirms timeline to initiate first-in-human trial for VYN201 in second half of 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-039716","json":"https://secwatch.observer/filing/0001104659-22-039716.json","markdown":"https://secwatch.observer/filing/0001104659-22-039716.md","text":"https://secwatch.observer/filing/0001104659-22-039716.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465922039716/0001104659-22-039716-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465922039716/tm228420d6_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T13:28:18.147063+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}